Preclinical Success to Clinical Failure: Do We Have a Model Problem or an Endpoint Problem?

As the AACR (American Association for Cancer Research) Annual Meeting is fast approaching, many industry and academic scientists are busy preparing talks and posters for what they hope will be the next new wave in cancer therapy or the next “new and improved” preclinical model. However, while these may be long shots, it’s the scientific […]

Colo-205 as a Translational Imaging Model for Colorectal Cancer

As mentioned in our HT-29 Model Spotlight last October, colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States for men and women combined. The death rate from CRC has been declining over the past several decades and there are now more than one million CRC survivors in the United […]

Use of Luminex® Technology to Quantify Biomarkers and Provide Agent Efficacy

In recent years many researchers have focused on the analysis of circulating soluble cancer biomarkers as an indicator of the host immune response to oncogenesis.1,2,3 Multiple biomarkers can be quantified in order to fully characterize changes in homeostasis brought on by tumor growth and metastasis. The ability to multiplex tumor-type specific antigens and general immune […]

PC-3M-Luc-C6 – A Model for Prostate Carcinoma

Globally, prostate cancer is the second most common type of cancer in men.  Prostate cancer is found mainly in older men with approximately 99 percent occurring in men over the age of 50. In the United States, African American men are roughly 70 percent more likely to be diagnosed with […]

4T1-luc2: An Orthotopic Mammary Cancer Model to Support Novel Immuno-Oncology Drug Discovery

Breast cancer is the second most deadly malignancy after lung cancer in woman in the United States, with an estimated 246,000 new cases and 40,450 deaths expected in 2016. Many treatment options for breast cancer exist including surgery, radiotherapy, anti-estrogen therapy, targeted therapies (e.g., trastuzumab), and chemotherapy. Despite these therapeutic advances, metastatic disease remains a […]

Measuring Extracellular pH Within Tumors Using CEST MRI

pH is one of the key microenvironmental factors in the development of tumors. Tumor cells are often viewed as high lactate and H+ producers.1 Extracellular acidosis represents a threat to cell survival by modifying the intracellular pH (pHi), wherein a 0.1 pHi variation can disrupt multiple biological functions.2 Measurements of tumor extracellular pH (pHe) may […]

Immune Profile of the Neuro-2a Mouse Neuroblastoma Model by Flow Cytometry

Neuroblastoma is an extracranial tumor that arises from neural crest-derived progenitor cells. It is the most prevalent solid tumor in childhood and the most common tumor in infants less than one year of age. With up to 800 new cases diagnosed each year, in spite of aggressive multi-modal therapeutic approaches, the 5-year survival rate in […]

HT-29 as a Preclinical Model for Colorectal Cancer

For men and women combined, colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. The American Cancer Society estimates that over 49,000 individuals will die of CRC in 2016. Fortunately, the death rate from CRC has been declining in both men and women over […]

Longitudinal Evaluation of Orthotopic Lung Tumors With Imaging

Lung cancer is the most common cause of cancer related deaths for men and second for women (after breast cancer). Worldwide, 1.8 million diagnoses and 1.6 million deaths occur annually.1 While incidences have been decreasing over recent decades and advances in diagnosis and treatments are being made in cancer as […]

786-O (pMMP-LucNeo) – A Model for Renal Cell Carcinoma

Kidney cancer generally occurs in older people, with an average age of diagnosis at 64 years old. Kidney cancer is among the ten most common types of cancer in the United States, with an overall lifetime risk of approximately 1.6 percent. The most common form of kidney cancer is renal […]

Leveraging the Clinical Power of MRI in Preclinical Liver Tumor Imaging

The liver is an ideal organ for magnetic resonance imaging (MRI) due to its size, plus the inherent contrast it enables compared to other tissues and lesions; this results from the high iron content which acts as a natural MRI contrast agent. For such reasons, liver tumor MRI is a major area of clinical and […]

5TGM1-luc – A Syngeneic Murine Model for Multiple Myeloma

Multiple myeloma is a malignancy of plasma B cells and is the second most common hematological malignancy in the United States. Malignant myeloma cells accumulate in the bone marrow and ultimately replace normal hematopoetic stem cells, which results in progressive leukocyte deficiencies. Chemotherapeutic agents and proteasome inhibitors are standard-of-care front […]

Approaches for Preclinical Evaluation of Ovarian Cancer

Table 1: Ovarian Cancer Models Ovarian cancer is considered a relatively rare gynecologic malignancy but has one of the highest mortality rates due to the non-specific symptoms that occur in early stage disease. This results in most women being diagnosed with advanced stage disease. The incidence of ovarian cancer within […]

A549 – A Model for Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer-related deaths in the world with non-small cell lung cancer (NSCLC) making up about 85% of all lung cancer cases. With the identification of particular tyrosine kinase mutations, such as EGFR and ALK, targeted therapies shifted the paradigm of drug discovery for NSCLC. […]

In-Depth Myeloid Cell Characterization in the Murine Syngeneic CT.26 Colon Carcinoma Model by 10-Color Flow Cytometry

The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4 and anti-PD-1, has driven growing interest in methods that provide a mechanistic understanding of drug function. Development of new mono- and combination therapies with immune-modulatory effects requires more powerful immunophenotyping techniques capable of in depth cell characterization. During […]

Comparison of Bioluminescence and MR Imaging to Evaluate Orthotopic Glioma Models

Glioblastoma multiforme (GBM) (also called glioblastoma) is a fast-growing glioma that develops from star-shaped glial cells (astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. These tumors are usually highly malignant because the cells reproduce quickly and they are supported by a large network of blood vessels. GBM is the […]

CT26: Murine Colon Carcinoma

An estimated one in 20 people will develop colon cancer, making it one of the most frequently diagnosed cancers both in men and women. Due to improved screening methods, the overall incidence of colon cancer has declined during the past 20 years. However, it is still projected that only 40% […]

Quantify T Cell Biodistribution Non-Invasively in Animal and Human Subjects

MI Bioresearch (MI) is looking for expressions of interest from companies involved in CAR-T and T Cell Receptor therapies, regarding non-invasive cell tracking in vivo.  MI is using a validated MRI platform that can be used to label T cells and detect/track cells in rodents.1  This strategy can also be implemented in NHP studies and clinical […]

GL261: Syngeneic Murine Glioma Model

Glioblastomas are known to have a poor prognosis with median survival of nine months and only five to 10 percent of patients surviving up to two years. Conventional therapies include radiotherapies and surgical removal of the tumor in combination with chemotherapy. Unfortunately, these tumors can often be radioresistant and surgical […]

MV(4;11): A Model of Human AML (acute myeloid leukemia)

Acute myeloid leukemia (AML) is a malignant disorder of the progenitor cells in myeloid hematopoiesis and represents a genetically heterogeneous cancer. The onset of AML is thought to require cooperation between active proliferation and defects in myeloid differentiation, which often results in chromosomal translocation (Gilliland et al., 2004). The annual incidence of AML is ~1.8 per […]